



## **Protara Therapeutics to Participate in Upcoming Investor Conferences**

March 2, 2022

NEW YORK, March 02, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will participate in fireside chats at two upcoming virtual conferences:

- Cowen 42nd Annual Health Care Conference on March 9, 2022 at 9:10am ET
- Oppenheimer 32nd Annual Healthcare Conference on March 15, 2022 at 2:00pm ET

A live webcast of the fireside chats can be accessed by visiting the Events and Presentations section of the Company's website: <https://ir.protaratx.com>. The webcasts will be archived on the Company's website for 90 days following the presentations.

### **About Protara Therapeutics, Inc.**

Protara is committed to identifying and advancing transformative therapies for people with cancer and rare diseases with limited treatment options. Protara's portfolio includes its lead program, TARA-002, an investigational cell-based therapy being developed for the treatment of non-muscle invasive bladder cancer and lymphatic malformations, and IV Choline Chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure-associated liver disease. For more information, visit [www.protaratx.com](http://www.protaratx.com).

### **Company Contact:**

Justine O'Malley  
Protara Therapeutics  
[Justine.OMalley@protaratx.com](mailto:Justine.OMalley@protaratx.com)  
646-817-2836



Source: Protara Therapeutics